Ara h 2-specific IgE epitope-like peptides inhibit the binding of IgE to Ara h 2 and suppress lgE-dependent effector cell activation.
Ara h 2
ImmunoCAP inhibition
basophil activation test
epitopes
mast cell activation test
paratopes
peanut allergy
peptides
specific IgE
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
28
02
2023
received:
25
11
2022
accepted:
16
03
2023
medline:
9
6
2023
pubmed:
12
4
2023
entrez:
11
4
2023
Statut:
ppublish
Résumé
Clinical and experimental analyses indicate a pathognomonic role for allergen IgE crosslinking through epitope-paratope interactions as a major initial step in the cascade leading to effector cell activation and clinical manifestations of lgE-mediated food allergies. We aimed to undertake the initial development and assessment of Ara h 2-specific IgE epitope-like peptides that can bind to allergen-specific IgE paratopes and suppress effector cell activation. We performed biopanning, screening, IgE binding, selection and mapping of peptides. We generated synthetic peptides for use in all functional experiments. ImmunoCAP inhibition, basophil and mast cell activation tests, with LAD2 cells, a human mast cell line were performed. Twenty-six children or young adults who had peanut allergy were studied. We identified and selected three linear peptides (DHPRFNRDNDVA, DHPRYGP and DHPRFST), and immunoblot analyses revealed binding to lgE from peanut-allergic individuals. The peptide sequences were aligned to the disordered region corresponding to the loop between helices 2 and 3 of Ara h 2, and conformational mapping showed that the peptides match the surface of Ara h 2 and h 6 but not other peanut allergens. In ImmunoCAP inhibition experiments, the peptides significantly inhibit the binding of IgE to Ara h 2 (p < .001). In basophil and mast cell activation tests, the peptides significantly suppressed Ara h 2-induced effector cell activation (p < .05) and increased the half-maximal Ara h 2 effective concentration (p < .05). Binding of the peptides to specific IgEs did not induce activation of basophils or mast cells. These studies show that the indicated peptides reduce the allergenic activity of Ara h 2 and suppress lgE-dependent basophil and mast cell activation. These observations may suggest a novel therapeutic strategy for food allergy based on epitope-paratop blocking.
Sections du résumé
BACKGROUND
Clinical and experimental analyses indicate a pathognomonic role for allergen IgE crosslinking through epitope-paratope interactions as a major initial step in the cascade leading to effector cell activation and clinical manifestations of lgE-mediated food allergies. We aimed to undertake the initial development and assessment of Ara h 2-specific IgE epitope-like peptides that can bind to allergen-specific IgE paratopes and suppress effector cell activation.
METHODS
We performed biopanning, screening, IgE binding, selection and mapping of peptides. We generated synthetic peptides for use in all functional experiments. ImmunoCAP inhibition, basophil and mast cell activation tests, with LAD2 cells, a human mast cell line were performed. Twenty-six children or young adults who had peanut allergy were studied.
RESULTS
We identified and selected three linear peptides (DHPRFNRDNDVA, DHPRYGP and DHPRFST), and immunoblot analyses revealed binding to lgE from peanut-allergic individuals. The peptide sequences were aligned to the disordered region corresponding to the loop between helices 2 and 3 of Ara h 2, and conformational mapping showed that the peptides match the surface of Ara h 2 and h 6 but not other peanut allergens. In ImmunoCAP inhibition experiments, the peptides significantly inhibit the binding of IgE to Ara h 2 (p < .001). In basophil and mast cell activation tests, the peptides significantly suppressed Ara h 2-induced effector cell activation (p < .05) and increased the half-maximal Ara h 2 effective concentration (p < .05). Binding of the peptides to specific IgEs did not induce activation of basophils or mast cells.
CONCLUSIONS
These studies show that the indicated peptides reduce the allergenic activity of Ara h 2 and suppress lgE-dependent basophil and mast cell activation. These observations may suggest a novel therapeutic strategy for food allergy based on epitope-paratop blocking.
Substances chimiques
Epitopes
0
Antigens, Plant
0
Glycoproteins
0
Peptides
0
Immunoglobulin E
37341-29-0
Allergens
0
2S Albumins, Plant
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
636-647Informations de copyright
© 2023 The Authors. Clinical & Experimental Allergy published by John Wiley & Sons Ltd.
Références
Vickery BP, Vereda A, Casale TB, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med [Internet]. 2018;379:1991-2001.
Leonard SA, Laubach S, Wang J. Integrating oral immunotherapy into clinical practice [Internet]. J Allergy Clin Immunol. 2021;147:1-13.
Warren C, Lei D, Sicherer S, Schleimer R, Gupta R. Prevalence and characteristics of peanut allergy in US adults. J Allergy Clin Immunol [Internet]. 2021;147:2263-2270.e5.
Burks AW, Sampson HA, Plaut M, Lack G, Akdis CA. Treatment for food allergy [Internet]. J Allergy Clin Immunol. 2018;141:1-9.
Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393:2222-2232.
Fleischer DM, Greenhawt M, Sussman G, et al. Effect of Epicutaneous immunotherapy vs placebo on reaction to Peanut protein ingestion among children with Peanut allergy: the PEPITES randomized clinical trial. JAMA. 2019;321:946-955.
Scurlock AM, Burks AW, Sicherer SH, et al. Epicutaneous immunotherapy for treatment of peanut allergy: follow-up from the consortium for food allergy research. J Allergy Clin Immunol [Internet]. 2021;147:992-1003.e5.
Tscheppe A, Palmberger D, van Rijt L, et al. Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity. J Allergy Clin Immunol [Internet]. 2020;145:229-238.
Shreffler WG, Beyer K, Chu THT, Burks AW, Sampson HA. Microarray immunoassay: association of clinical history, in vitro IgE function, and heterogeneity of allergenic peanut epitopes. J Allergy Clin Immunol. 2004;113:776-782.
Nicolaou N, Poorafshar M, Murray C, et al. Allergy or tolerance in children sensitized to peanut: prevalence and differentiation using component-resolved diagnostics. J Allergy Clin Immunol [Internet]. 2010;125:191-197.e13.
Dang TD, Tang M, Choo S, et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. J Allergy Clin Immunol. 2012;129:1056-1063.
Klemans RJB, Broekman HCHP, Knol EF, et al. Ara h 2 is the best predictor for Peanut allergy in adults. J Allergy Clin Immunol Pract. 2013;1:632-638.e1.
Kansen HM, van Erp FC, Knulst AC, et al. Accurate prediction of Peanut allergy in one-third of adults using a validated Ara h 2 cutoff. J Allergy Clin Immunol Pract [Internet]. 2021;9:1667-1674.e3.
Bahri R, Custovic A, Korosec P, et al. Mast cell activation test in the diagnosis of allergic disease and anaphylaxis. J Allergy Clin Immunol. 2018;142:485-496.e16.
Hemmings O, Du Toit G, Radulovic S, Lack G, Santos AF. Ara h 2 is the dominant peanut allergen despite similarities with Ara h 6. J Allergy Clin Immunol [Internet]. 2020;146:621-630.e5.
Otsu K, Guo R, Dreskin SC. Epitope analysis of Ara h 2 and Ara h 6: characteristic patterns of IgE-binding fingerprints among individuals with similar clinical histories. Clin Exp Allergy [Internet]. 2015;45:471-484.
Stanley JSS, King N, Burks AWW, et al. Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Arch Biochem Biophys [Internet]. 1997;342:244-253.
Shreffler WG, Lencer DA, Bardina L, Sampson HA. IgE and IgG4 epitope mapping by microarray immunoassay reveals the diversity of immune response to the peanut allergen, Ara h 2. J Allergy Clin Immunol. 2005;116:893-899.
Flinterman AE, Knol EF, Lencer DA, et al. Peanut epitopes for IgE and IgG4 in peanut-sensitized children in relation to severity of peanut allergy. J Allergy Clin Immunol. 2008;121:737-743.e10.
Suárez-Fariñas M, Suprun M, Kearney P, et al. Accurate and reproducible diagnosis of peanut allergy using epitope mapping. 2021;76:3789-3797.
Suarez-Farinas M, Suprun M, Bahnson HT, et al. Evolution of epitope-specific IgE and IgG 4 antibodies in children enrolled in the LEAP trial. J Allergy Clin Immunol [Internet]. 2021;148:835-842.
Santos AF, Barbosa-Morais NL, Hurlburt BK, et al. IgE to epitopes of Ara h 2 enhance the diagnostic accuracy of Ara h 2-specific IgE. Allergy Eur. J Allergy Clin Immunol [Internet]. 2020;75:2309-2318.
Suprun M, Sicherer SH, Wood RA, et al. Early epitope-specific IgE antibodies are predictive of childhood peanut allergy. J Allergy Clin Immunol [Internet]. 2020;146:1080-1088.
Croote D, Darmanis S, Nadeau KC, Quake SR. High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes. Science [Internet]. 2018;362:1306-1309.
Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med [Internet]. 2012;18:693-704.
Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J Allergy Clin Immunol [Internet]. 2017;140:335-348.
Dang TD, Tang M, Choo S, et al. Increasing the accuracy of peanut allergy diagnosis by using Ara h 2. J Allergy Clin Immunol [Internet]. 2012;129:1056-1063.
Zahirović A, Štrukelj B, Korošec P, Lunder M. Epitope mapping of major ragweed allergen AMB a 1. Acta Chim Slov. 2019;66:37-44.
Luzar J, Molek P, Šilar M, et al. Identification and characterization of major cat allergen Fel d 1 mimotopes on filamentous phage carriers. Mol Immunol. 2016;71:176-183.
Zahirović A, Koren A, Kopač P, Štrukelj B, Korošec P, Lunder M. Identification of bee venom Api m 1 IgE epitopes and characterization of corresponding mimotopes. J Allergy Clin Immunol. 2019;143:791-794.e5.
Pepitope Server [Internet]. http://pepitope.tau.ac.il/. Accessed August 5, 2021.
Kelley LA, Sternberg MJE. PHYRE2 protein fold recognition server [Internet]. Nat Protoc. 2009;4:363-371.
Amoah AS, Obeng BB, Larbi IA, et al. Peanut-specific IgE antibodies in asymptomatic Ghanaian children possibly caused by carbohydrate determinant cross-reactivity. J Allergy Clin Immunol. 2013;132:639-647.
Kosnik M, Silar M, Bajrovic N, Music E, Korosec P. High sensitivity of basophils predicts side-effects in venom immunotherapy. Allergy [Internet]. 2005;60:1401-1406.
Homšak M, Šilar M, Berce V, et al. The relevance of basophil allergen sensitivity testing to distinguish between severe and mild peanut-allergic children. Int Arch Allergy Immunol. 2013;162:310-317.
Kopač P, Custovic A, Zidarn M, et al. Biomarkers of the severity of honeybee sting reactions and the severity and threshold of systemic adverse events during immunotherapy. J Allergy Clin Immunol Pract. 2021;9:3157-3163.e5.
Kirshenbaum AS, Akin C, Wu Y, et al. Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcεRI or FcγRI. Leuk Res. 2003;27:677-682.
Santos AF, Couto-Francico N, Bécares N, Kwok M, Bahnson HT, Lack G. A novel human mast cell activation test for peanut allergy. J Allergy Clin Immunol. 2018;142:689-691.e9.
Mueller GA, Gosavi RA, Pomés A, et al. Ara h 2: crystal structure and IgE binding distinguish two subpopulations of peanut allergic patients by epitope diversity. Allergy Eur J Allergy Clin Immunol. 2011;66:878-885.
Stanley JS, King N, Burks AW, et al. Identification and mutational analysis of the immunodominant ige binding epitopes of the major peanut allergen Ara h 2. Arch Biochem Biophys. 1997;342:244-253.
Hazebrouck S, Patil SU, Guillon B, et al. Immunodominant conformational and linear IgE epitopes lie in a single segment of Ara h 2. J Allergy Clin Immunol [Internet]. 2022;150:131-139.
Smit JJ, Willemsen K, Hassing I, et al. Contribution of classic and alternative effector pathways in Peanut-induced anaphylactic responses. PLoS One [Internet]. 2011;6:e28917. doi:10.1371/journal.pone.0028917
Liu T, Navarro S, Lopata AL. Current advances of murine models for food allergy. Mol Immunol. 2016;70:104-117.
Gertie JA, Zhang B, Liu EG, et al. Oral anaphylaxis to peanut in a mouse model is associated with gut permeability but not with Tlr4 or Dock8 mutations. J Allergy Clin Immunol [Internet]. 2022;149:262-274.
Chen X, Negi SS, Liao S, Gao V, Braun W, Dreskin SC. Conformational IgE epitopes of peanut allergens Ara h 2 and Ara h 6. Clin Exp Allergy. 2016;46:1120-1128.
Suprun M, Getts R, Raghunathan R, et al. Novel bead-based epitope assay is a sensitive and reliable tool for profiling epitope-specific antibody repertoire in food allergy. Sci Rep [Internet]. 2019;9:18425.